Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Nivolumab Safety Study in Advanced or Metastatic NSCLC (Japan)
jRCT2080223662Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223662.